Advanced delivery of ciclosporin A: present state and perspective
- PMID: 17683249
- DOI: 10.1517/17425247.4.4.349
Advanced delivery of ciclosporin A: present state and perspective
Abstract
Ciclosporin A has been used as an immunosuppressor for organ transplantation and other autoimmune disorders for a number of years. Its poor biopharmaceutical characteristics of low solubility and permeability makes the uphill task of designing delivery systems even more challenging for the drug delivery scientist. Works have been performed to investigate administration through various body routes, and have employed approaches that use as emulsions, microspheres, nanoparticles, liposomes, physical and chemical penetration enhancers. Although progress has been made, there is still room for improvement in the application of ciclosporin A, as none of these formulations is ideal.
Similar articles
-
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.Drug Discov Today. 2006 Sep;11(17-18):846-54. doi: 10.1016/j.drudis.2006.07.015. Drug Discov Today. 2006. PMID: 16935754 Review.
-
Oral cyclosporine A--the current picture of its liposomal and other delivery systems.Cell Mol Biol Lett. 2009;14(1):139-52. doi: 10.2478/s11658-008-0041-6. Epub 2008 Nov 12. Cell Mol Biol Lett. 2009. PMID: 19005620 Free PMC article. Review.
-
Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.Int J Nanomedicine. 2015 Oct 16;10:6541-53. doi: 10.2147/IJN.S90849. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26527872 Free PMC article.
-
Characterization of ciclosporin A loaded poly (D,L lactide-co-glycolide) microspheres using modulated temperature differential scanning calorimetry.J Pharm Pharmacol. 2002 Jul;54(7):913-9. doi: 10.1211/002235702760089027. J Pharm Pharmacol. 2002. PMID: 12162709
-
Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.Eur J Pharm Biopharm. 2009 Oct;73(2):247-52. doi: 10.1016/j.ejpb.2009.06.011. Epub 2009 Jun 26. Eur J Pharm Biopharm. 2009. PMID: 19560537
Cited by
-
Recent advances in ophthalmic drug delivery.Ther Deliv. 2010 Sep;1(3):435-56. doi: 10.4155/TDE.10.40. Ther Deliv. 2010. PMID: 21399724 Free PMC article. Review.
-
Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.Br J Pharmacol. 2014 Sep;171(17):3988-4000. doi: 10.1111/bph.12722. Epub 2014 Jul 2. Br J Pharmacol. 2014. PMID: 24724793 Free PMC article. Review.
-
Norine: A powerful resource for novel nonribosomal peptide discovery.Synth Syst Biotechnol. 2016 Jun 1;1(2):89-94. doi: 10.1016/j.synbio.2015.11.001. eCollection 2016 Jun. Synth Syst Biotechnol. 2016. PMID: 29082924 Free PMC article. Review.
-
An overview on dry eye treatment: approaches for cyclosporin a delivery.ScientificWorldJournal. 2012;2012:194848. doi: 10.1100/2012/194848. Epub 2012 Apr 24. ScientificWorldJournal. 2012. PMID: 22619624 Free PMC article. Review.
-
New agents for treating dry eye syndrome.Curr Allergy Asthma Rep. 2013 Jun;13(3):322-8. doi: 10.1007/s11882-012-0321-0. Curr Allergy Asthma Rep. 2013. PMID: 23129303 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources